Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter ... DailyFinance We estimate that approximately $82 million of TECFIDERA revenues in the second quarter represent inventory in the channel while revenue generated from underlying patient demand was approximately $110 million. RITUXAN® (rituximab) revenues from ... Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results - Earnings Call ... |
